Last updated: 02/04/2020 18:50:17

META REGRESSION ANALYSIS TO INDIRECTLY COMPARE ELTROMBOPAG TO ROMIPLOSTIM FOR THE TREATMENT OF IDIOPATHIC THROMBOCYTOPENIA

GSK study ID
117347
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: META REGRESSION ANALYSIS TO INDIRECTLY COMPARE ELTROMBOPAG TO ROMIPLOSTIM FOR THE TREATMENT OF IDIOPATHIC THROMBOCYTOPENIA
Trial description: The purpose of this study is to conduct an indirect comparison on the safety and efficacy between eltrombopag and romiplostim in patients with chronic idiopathic thrombocytopenia (ITP).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Platelet Response

Timeframe: 6 weeks - 6 months

Secondary outcomes:

Discontinuation due to AEs

Timeframe: 6 weeks - 6 months

Interventions:
  • Drug: Eltrombopag
  • Drug: Romiplostim
    • Enrollment:
    0
    Primary completion date:
    2013-26-08
    Observational study model:
    Other
    Time perspective:
    Retrospective
    Clinical publications:
    Not applicable
    Medical condition
    Thrombocytopaenia
    Product
    eltrombopag
    Collaborators
    Augmentium Pharma Consulting
    Study date(s)
    December 2008 to August 2013
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    none
    • Studies must at least 10 patients enrolled into each treatment group
    • Patients must have been adults 18 years of age or older
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Studies must at least 10 patients enrolled into each treatment group
    • Patients must have been adults 18 years of age or older
    • Diagnosed with chronic ITP that had relapsed after at least one treatment
    • Randomized trials presented in abstract form at professional meetings were also eligible, provided that access to the full study reports was available

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2013-26-08
    Actual study completion date
    2013-26-08

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website